Klaus has 25 years of experience as a biotech executive and entrepreneur. He has worked on different modalities to bring precision oncology therapies to patients: As such, in his current function as CFO at ITM SE, he leads the efforts to develop radiopharmaceuticals against a broad range of cancer targets. As CEO at TETEC AG, he built up a leading company in the cell and gene therapy field, and as co-owner of Intavis Peptides GmbH, he fosters the development of patient-specific peptide cancer vaccines.
Klaus is also member of the Boards of several biotech companies and of BioDeutschland e.V. He is an operating partner at ArchiMed SAS, a specialized health care investor. Prior to these engagements, he worked as a research scientist at Novartis Inc., was a consultant at McKinsey & Co, and worked as founding CFO at pioneering biosimilar company BioGeneriX AG and as CFO at Evotec AG.